Earnings Call · Q3 FY2024·2024-11-14

Q3 24EPS +21.24%·Rev n/aQ2 24EPS -8.18%·Rev n/aQ1 24EPS -32.32%·Rev n/aQ4 23EPS +11.81%·Rev n/a⚠ consensus missing

INOVIO PHARMACEUTICALS, INC. INO

Thomas Hong — Unknown

Jacqui Shea — President and Chief Executive Officer

Mike Sumner — Chief Medical Officer

Steve Egge — Chief Commercial Officer

Peter Kies — Chief Financial Officer

−3.6%1d on move date−3.0% vs SPY3d−17.6%5d−19.8%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more INO calls or request research access.

More INO calls Browse calls Request research access